AR
AROAF.US Aroa Biosurgery Limited
- Market cap
- USD 166M
- P/E
- 47.3x
- P/B
- 2.91x
- ROE
- 4.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Mar 2026.
Is AROAF.US undervalued?
Graham numberAROAF.US trades 147.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aroa Biosurgery Limited fundamental analysis
No fundamental analysis for Aroa Biosurgery Limited yet.
Aroa Biosurgery Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aroa Biosurgery Limited
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symp…
Full company profileAroa Biosurgery Limited financial statements
Aroa Biosurgery Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 20.5M | 36.9M | 59.3M | 63.4M | 77.0M | 86.6M |
| Gross Profit | 14.3M | 28.2M | 50.1M | 54.1M | 66.0M | 74.1M |
| Operating Income | -14.4M | -11.1M | -8.13M | -15.3M | -8.13M | -520K |
| EBITDA | - | - | 3.24M | -4.37M | 2.65M | 9.92M |
| Net Income | -17.6M | -7.79M | -371K | -9.75M | -3.47M | 3.90M |
| EPS | -0.06 | -0.02 | 0.00 | -0.03 | -0.01 | 0.01 |
| Balance Sheet | ||||||
| Total Assets | 73.1M | 105M | 109M | 102M | 98.9M | 101M |
| Total Liabilities | 19.4M | 11.3M | 13.7M | 14.8M | 14.3M | 17.8M |
| Shareholders' Equity | 53.7M | 93.4M | 95.4M | 87.1M | 84.6M | 82.8M |
| Cash & Short-term Investments | 32.5M | 5.73M | 8.93M | 10.6M | 7.26M | 17.6M |
| Cash Flow | ||||||
| Capital Expenditure | 1.38M | 4.53M | 7.12M | 6.41M | 3.36M | 3.11M |
| Free Cash Flow | -5.97M | -15.2M | -10.7M | -13.2M | -5.69M | 5.68M |
| Ratios | ||||||
| ROE | -32.8% | -8.3% | -0.4% | -11.2% | -4.1% | 4.7% |
| ROA | -24.1% | -7.4% | -0.3% | -9.6% | -3.5% | 3.9% |
| Net Profit Margin | -86.0% | -21.1% | -0.6% | -15.4% | -4.5% | 4.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Aroa Biosurgery Limited dividends
Aroa Biosurgery Limited has not paid dividends in the last 6 fiscal years.
Who owns Aroa Biosurgery Limited
- Insiders 27.29%
- Institutions 34.09%
- Public & others 38.63%
- Shares outstanding 351M
- Free float 260M
Aroa Biosurgery Limited company profile
- Company name
- Aroa Biosurgery Limited
- Ticker
- AROAF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- March
- Address
- 64 Richard Pearse Drive, Auckland, New Zealand, 2022
- Phone
- 64 9 869 3035
- Website
- aroa.com
About Aroa Biosurgery Limited
Aroa Biosurgery Limited develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally. Its products include Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold for treating acute and chronic wounds; Myriad Matrix, an engineered ECM for soft tissue repair, reinforcement, and complex wounds; and Myriad Morcells, Myriad Morcells Fine, Myriad Meshed, and Symphony products for the treatment of partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds, trauma wounds, and draining wounds. The company also develops products for abdominal wall reconstruction, hernia repair, and breast reconstruction in North America and Europe. Aroa Biosurgery Limited was incorporated in 2007 and is headquartered in Auckland, New Zealand.
Aroa Biosurgery Limited management
9- Dr. Brian Ward B.V.Sc, MBA(dist)Founder, CEO, MD & Executive Director
- Mr. James Agnew BCom, LLBCFO & Joint Company Secretary
- Mr. Rod Stanley M.Sc.Chief Operating Officer
- Ms. Yasmin Winchester B.Sc.Chief of Technical Operations
- Dr. Barnaby C.H. May Ph.D.Chief Scientific Officer
- Mr. Michael LynskeyChief Commercial Officer
- Ms. Tracy Weimar BA, MBAJoint Company Secretary
- Mr. Adam Young Ph.D.Vice President of Medical Affairs
- Sarah ToraMedia Executive